USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 7,289 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $66.01, for a total value of $481,146.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Global Ltd Gull also recently made the following trade(s):

  • On Thursday, November 2nd, Global Ltd Gull sold 43,292 shares of USANA Health Sciences stock. The shares were sold at an average price of $65.25, for a total value of $2,824,803.00.
  • On Thursday, October 26th, Global Ltd Gull sold 60,871 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.39, for a total value of $4,102,096.69.
  • On Monday, October 30th, Global Ltd Gull sold 93,443 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.08, for a total value of $6,268,156.44.
  • On Thursday, September 14th, Global Ltd Gull sold 79,294 shares of USANA Health Sciences stock. The shares were sold at an average price of $57.61, for a total value of $4,568,127.34.
  • On Tuesday, September 5th, Global Ltd Gull sold 40,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $58.41, for a total value of $2,336,400.00.

USANA Health Sciences, Inc. (NYSE:USNA) opened at $65.95 on Wednesday. USANA Health Sciences, Inc. has a 12-month low of $52.55 and a 12-month high of $71.00. The stock has a market capitalization of $1,579.91, a P/E ratio of 17.42 and a beta of 1.07.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.11. USANA Health Sciences had a return on equity of 26.38% and a net margin of 8.79%. The firm had revenue of $261.77 million during the quarter, compared to the consensus estimate of $259.52 million. During the same quarter in the prior year, the firm posted $2.40 EPS. The business’s revenue was up 3.0% on a year-over-year basis. equities research analysts expect that USANA Health Sciences, Inc. will post 3.7 EPS for the current year.

USANA Health Sciences declared that its board has authorized a share repurchase program on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to buy up to 46% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: “Global Ltd Gull Sells 7,289 Shares of USANA Health Sciences, Inc. (USNA) Stock” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/15/global-ltd-gull-sells-7289-shares-of-usana-health-sciences-inc-usna-stock.html.

A number of large investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. boosted its position in USANA Health Sciences by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 8,349 shares of the company’s stock worth $535,000 after acquiring an additional 22 shares during the last quarter. California State Teachers Retirement System boosted its position in USANA Health Sciences by 0.5% during the 2nd quarter. California State Teachers Retirement System now owns 20,582 shares of the company’s stock worth $1,319,000 after acquiring an additional 100 shares during the last quarter. JPMorgan Chase & Co. boosted its position in USANA Health Sciences by 1.2% during the 1st quarter. JPMorgan Chase & Co. now owns 16,044 shares of the company’s stock worth $924,000 after acquiring an additional 196 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in USANA Health Sciences by 13.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock worth $135,000 after acquiring an additional 245 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in USANA Health Sciences by 7.6% during the 2nd quarter. Legal & General Group Plc now owns 4,040 shares of the company’s stock worth $259,000 after acquiring an additional 284 shares during the last quarter. 44.54% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on USNA shares. Pivotal Research boosted their price objective on USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. BidaskClub upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.